I-Mab Biopharma
IMAB
#9166
Rank
NZ$0.15 B
Marketcap
$1.90
Share price
-1.38%
Change (1 day)
-30.51%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): NZ$5.7 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is NZ$6.33 Million. In 2022 the company made a revenue of -NZ$56.69 Million a decrease over the revenue in the year 2021 that were of NZ$24.37 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$5.7 M
2022-NZ$56.69 Million-332.55%
2021NZ$24.37 M-94.16%
2020 NZ$0.41 B5407.66%
2019 NZ$7.57 M-45.08%
2018 NZ$13.79 M340.25%
2017NZ$3.13 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NZ$0.39 M-93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.25 B 19,728.62%๐Ÿ‡บ๐Ÿ‡ธ USA